GNPX Stock Overview
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Genprex, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.74 |
52 Week High | US$46.00 |
52 Week Low | US$2.70 |
Beta | -0.57 |
1 Month Change | -37.16% |
3 Month Change | -68.51% |
1 Year Change | -92.63% |
3 Year Change | -98.32% |
5 Year Change | -95.92% |
Change since IPO | -98.54% |
Recent News & Updates
Recent updates
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?
Aug 16Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation
Jan 31Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans
Oct 12Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer
Aug 15We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate
Jun 14Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation
Feb 09Genprex: Limited Clinical Data To Justify Risk
Nov 19We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth
Oct 27Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans
Jun 11Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%
May 05Genprex' stock jumps after corporate update
Feb 01Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials
Jan 13Genprex completes manufacturing scale-up of lung cancer therapy
Dec 22Shareholder Returns
GNPX | US Biotechs | US Market | |
---|---|---|---|
7D | -18.9% | -0.5% | 0.6% |
1Y | -92.6% | 9.6% | 29.5% |
Return vs Industry: GNPX underperformed the US Biotechs industry which returned 10.2% over the past year.
Return vs Market: GNPX underperformed the US Market which returned 29.8% over the past year.
Price Volatility
GNPX volatility | |
---|---|
GNPX Average Weekly Movement | 18.1% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GNPX's share price has been volatile over the past 3 months.
Volatility Over Time: GNPX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 31 | John Varner | https://www.genprex.com |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes.
Genprex, Inc. Fundamentals Summary
GNPX fundamental statistics | |
---|---|
Market cap | US$4.46m |
Earnings (TTM) | -US$31.45m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs GNPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GNPX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$31.45m |
Earnings | -US$31.45m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -21.17 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did GNPX perform over the long term?
See historical performance and comparison